281.5K views | +22 today

Engaging Patients Through Social Media | IMS Institute


IMS's Top 10 Pharma Social Media Engagers

By Ben Comer | Published: January 21, 2014

The IMS Institute for Healthcare Informatics worked up a methodology for assessing the effectiveness of pharma’s social media efforts across Facebook, Twitter and YouTube, according to three indices: reach (total number of people reached through each channel via likes, shares and re-tweets); relevance (extent to which content is being shared and forwarded); and relationship (amount of back and forth between company and patient).

Those pharmas hitting the trifecta scored best on the cumulative “Social Media Engagement Index.” Results were tallied over a two-year period. Here are the top ten pharma engagers, per IMS Health. To read the full report, which discusses the role of Wikipedia, healthcare professionals’ use of social media, and a summary of social media regulatory policy in the US, Canada and the EU, click here. And the winners are:


IMS Health Social Engagement Index

1. Johnson & Johnson

2. GlaxoSmithKline

3.Novo Nordisk

4. Pfizer

5. Novartis

6. Boehringer Ingelheim

7. Bayer

8. Merck

9. AstraZeneca

10. UCB

In a separate article, consultants at Capgemini Consulting Life Sciences wonder if social media in pharma has reached a tipping point. PharmExec’s sibling company, CBI, is hosting its annual iPharma conference in New York City this May.

rob halkes's curator insight, February 3, 2014 10:12 AM

It says that the self evident suspects have done the trick of social media again. What has it brought to them, besides being positioned in these lists. Has thier image raised for patients and physicians, the public in gerenal? I guess they know it, but we don't see publications of it. Do we?

Indeed there's a tipping point reached in what a pharma company may reach in doing social media in their engagement to the public in general. Now there's the time to develop their information (and promotion) channel in to interactive channels, producing support and collaboration to improve patient care. That is however, a much more challenging demand than using just social media with a multichannel mix. It depends upon their strategic starting point of what pharma wants to do for its commercial development. Now is the move to upper management  ;-)